Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | REN | P00797 | 1/20 | 0.66 |
| ▸ | TACR1 | P25103 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.61 |
| ▸ | ECE1 | P42892 | 2/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP14 | P50281 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | BMP1 | P13497 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027229 | 1.00 | NMBR (0.71) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL5380023 | 1.00 | NMBR (0.71) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL11765479 | 1.00 | NMBR (0.71) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL5380441 | 0.98 | NMBR (0.74) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL14595064 | 0.98 | NMBR (0.74) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL1318661 | 0.94 | NMBR (0.73) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL29401413 | 0.94 | NMBR (0.73) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL17319524 | 0.94 | NMBR (0.73) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL11330243 | 0.93 | NMBR (0.70) | NMBRMAPTLMNAGAAHTT | |
| SCHEMBL29828016 | 0.92 | NMBR (0.69) | NMBRMAPTLMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | NMBR 386/4885MAPT 4850/4885LMNA 3345/4885 |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | NMBR 386/4885MAPT 4850/4885LMNA 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.